search
Back to results

Rebalancing the Serotonergic System in Cocaine Dependence

Primary Purpose

Cocaine Dependence

Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Lorcaserin
Placebo Oral Tablet
Sponsored by
Mclean Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Cocaine Dependence

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • - Participants will be male and female volunteers between the ages of 18-55
  • Participants will report having used cocaine on at least four occasions within the month prior to screening; the urine sample obtained during the screening visit must be positive for the cocaine metabolite benzoylecgonine (>300 ng/ml). They can meet DSM-IV criteria for cocaine abuse and dependence.
  • Participants cannot meet DSM-IV criteria for current psychotic disorders (e.g., bipolar disorder, schizophrenia, schizoaffective disorder)
  • Participants cannot meet DSM-IV criteria for a current major depressive episode
  • Participants cannot meet DSM-IV criteria for current drug dependence (except nicotine, cocaine, and marihuana)
  • Participants must test negative for alcohol use on the day of the scan.
  • Participants can report current abuse of marihuana and tobacco. Participants cannot have used marihuana within twelve hours of their study visits.
  • Participants cannot be regular opiate users including prescription opiate analgesics
  • Participants cannot have a history of major head trauma resulting in cognitive impairment, seizure, or other neurological disorders.
  • Participants cannot have any conditions that are contraindicated for MRI (see next section)
  • Participants cannot be pregnant (pregnancy test will be performed before each scanning session)
  • Participants must be able to read screening materials including consent form and give informed consent
  • Participants cannot be taking any medications with a 5-HT mechanism including serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and St. John's Wort and tryptophan.
  • Participants cannot be currently taking any medications that might affect the central nervous system including prescription analgesics, anxiolytics, antipsychotics, and antidepressants. A complete review of medications will be evaluated by study staff.
  • Cannot have any history of a medical condition that might affect the central nervous system at the time of scanning including: Abnormal structural MRI, or a history of head trauma or injury causing loss of consciousness lasting longer than 3 minutes or associated with skull fracture or intracranial bleeding or who had irremovable magnetically active objects on or within their body, or history of epilepsy.

Exclusion Criteria:

  • - Weight greater than 350 pounds (cannot easily fit inside the magnet bore)
  • Cardiac pacemakers
  • Aneurysm clips and other vascular stents, filters, clips or other devices
  • Prosthetic heart valves
  • Other prostheses
  • Neuro-stimulator devices
  • Implanted infusion pumps
  • Cochlear implants
  • Ocular implants or known metal fragments in eyes
  • Exposure to shrapnel or metal filings (sheet metal workers, welders, and others)
  • Other metallic surgical hardware in vital areas
  • History of major head trauma resulting in cognitive impairment
  • Certain tattoos (e.g. older dye with metallic pigment)
  • Certain medication patches (if they cannot be removed)
  • Metal containing IUDs
  • Claustrophobia
  • Pregnancy
  • Metallic implants except fillings and crowns
  • Tattoos containing metallic ink on the neck, shoulders, upper arm, and head (these could become heated during scanning, potentially causing burns
  • Medication patches that cannot be removed during scanning
  • Claustrophobia

Sites / Locations

  • McLean Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo

Active Medication

Arm Description

Outcomes

Primary Outcome Measures

Influence of lorcaserin on fMRI measured brain-reactivity to drug cues.

Secondary Outcome Measures

Full Information

First Posted
August 23, 2017
Last Updated
February 22, 2021
Sponsor
Mclean Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03266939
Brief Title
Rebalancing the Serotonergic System in Cocaine Dependence
Official Title
Rebalancing the Serotonergic System in Cocaine Dependence
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
October 4, 2018 (Actual)
Primary Completion Date
December 2021 (Anticipated)
Study Completion Date
December 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mclean Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
In the United States, 1.5 million people abuse cocaine leading to a host of negative health and economic consequences, yet no FDA approved treatment exists. To develop effective treatments, the following must be considered: 1) do potential medications ameliorate brain disruptions associated with cocaine use? 2) are multiple, targeted treatments necessary? To meet these goals, innovative multi-modal neuroimaging will be used to determine whether rebalancing the serotonergic (5-HT) system reduces cocaine cue reactivity, impulsivity, and normalizes related neurochemistry and brain connectivity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine Dependence

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
Active Medication
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Lorcaserin
Intervention Description
10 mg acute administration of lorcasein
Intervention Type
Drug
Intervention Name(s)
Placebo Oral Tablet
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Influence of lorcaserin on fMRI measured brain-reactivity to drug cues.
Time Frame
fMRI measures will be gathered on scanning visits 1 and 2 (approx 1 week apart)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Participants will be male and female volunteers between the ages of 18-55 Participants will report having used cocaine on at least four occasions within the month prior to screening; the urine sample obtained during the screening visit must be positive for the cocaine metabolite benzoylecgonine (>300 ng/ml). They can meet DSM-IV criteria for cocaine abuse and dependence. Participants cannot meet DSM-IV criteria for current psychotic disorders (e.g., bipolar disorder, schizophrenia, schizoaffective disorder) Participants cannot meet DSM-IV criteria for a current major depressive episode Participants cannot meet DSM-IV criteria for current drug dependence (except nicotine, cocaine, and marihuana) Participants must test negative for alcohol use on the day of the scan. Participants can report current abuse of marihuana and tobacco. Participants cannot have used marihuana within twelve hours of their study visits. Participants cannot be regular opiate users including prescription opiate analgesics Participants cannot have a history of major head trauma resulting in cognitive impairment, seizure, or other neurological disorders. Participants cannot have any conditions that are contraindicated for MRI (see next section) Participants cannot be pregnant (pregnancy test will be performed before each scanning session) Participants must be able to read screening materials including consent form and give informed consent Participants cannot be taking any medications with a 5-HT mechanism including serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and St. John's Wort and tryptophan. Participants cannot be currently taking any medications that might affect the central nervous system including prescription analgesics, anxiolytics, antipsychotics, and antidepressants. A complete review of medications will be evaluated by study staff. Cannot have any history of a medical condition that might affect the central nervous system at the time of scanning including: Abnormal structural MRI, or a history of head trauma or injury causing loss of consciousness lasting longer than 3 minutes or associated with skull fracture or intracranial bleeding or who had irremovable magnetically active objects on or within their body, or history of epilepsy. Exclusion Criteria: - Weight greater than 350 pounds (cannot easily fit inside the magnet bore) Cardiac pacemakers Aneurysm clips and other vascular stents, filters, clips or other devices Prosthetic heart valves Other prostheses Neuro-stimulator devices Implanted infusion pumps Cochlear implants Ocular implants or known metal fragments in eyes Exposure to shrapnel or metal filings (sheet metal workers, welders, and others) Other metallic surgical hardware in vital areas History of major head trauma resulting in cognitive impairment Certain tattoos (e.g. older dye with metallic pigment) Certain medication patches (if they cannot be removed) Metal containing IUDs Claustrophobia Pregnancy Metallic implants except fillings and crowns Tattoos containing metallic ink on the neck, shoulders, upper arm, and head (these could become heated during scanning, potentially causing burns Medication patches that cannot be removed during scanning Claustrophobia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amy Janes, PhD
Organizational Affiliation
Mclean Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
McLean Hospital
City
Belmont
State/Province
Massachusetts
ZIP/Postal Code
02478
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Rebalancing the Serotonergic System in Cocaine Dependence

We'll reach out to this number within 24 hrs